LGND / Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $53.30, indicating a +1.93% shift from the previous trading day. more_horizontal

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Pre more_horizontal

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $52.09, denoting a -1.31% change from the preceding trading day. more_horizontal

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $58.84, indicating a +1.19% shift from the previous trading day. more_horizontal

Ligand (LGND) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat i more_horizontal

Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform more_horizontal

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own more_horizontal

Ligand Pharmaceuticals Incorporated generates revenue through licensing technologies, contractual fees, and the sale of Captisol, a modified cyclodext more_horizontal